Gilead Sciences to Acquire Arcellx for $7.8 Billion in Cash and CVRs
Summary
Gilead Sciences, Inc. has filed a Schedule 13D detailing its definitive agreement to acquire Arcellx, Inc. for approximately $7.8 billion, offering $115.00 per share in cash plus a $5.00 contingent value right.
Key Events
-
Definitive Acquisition Agreement
Gilead Sciences, Inc. will acquire Arcellx, Inc. for approximately $7.8 billion. Shareholders will receive $115.00 per share in cash plus one contingent value right (CVR) worth $5.00 upon milestone achievement.
-
Existing Strategic Stake
Gilead currently holds 6,720,803 shares, representing an 11.5% beneficial ownership stake in Arcellx, acquired through prior stock purchase agreements in 2023 and 2024.
-
Tender and Support Agreements
Key Arcellx shareholders, including directors and officers, collectively owning approximately 10.3% of outstanding shares, have entered into agreements to tender their shares in the offer.
-
Planned Delisting
Following the merger, Arcellx will become a wholly-owned subsidiary of Gilead, and its shares will be delisted from the Nasdaq Global Select Market.
Analysis
This Schedule 13D confirms and provides the detailed legal framework for the acquisition of Arcellx by Gilead Sciences, following the concurrent SC TO-C filing. Gilead will acquire all outstanding shares of Arcellx for $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share upon achievement of a specified milestone. This represents a significant premium over Arcellx's recent trading price and market capitalization, offering a clear exit for shareholders. Gilead already held an 11.5% stake in Arcellx, built through prior strategic investments in 2023 and 2024, stemming from a collaboration agreement. The acquisition will be executed via a tender offer, followed by a merger, and will result in Arcellx becoming a wholly-owned subsidiary of Gilead and its subsequent delisting from Nasdaq. The Tender and Support Agreements with key shareholders, including directors and officers, representing approximately 10.3% of outstanding shares, underscore the high likelihood of the transaction's completion.
At the time of this filing, ACLX was trading at $114.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $47.86 to $94.07. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.